Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Intefen
- Development stage
- Unknown
- Lead developer
- 3SBio
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous, Intralesional
01
Overview
Intefen is a recombinant human interferon alpha-2a (IFN-α-2a) developed by 3SBio Inc. It is a biologic drug that exhibits broad-spectrum antiviral, antitumor, and immunomodulatory activities. By binding to the Type I interferon receptor (IFNAR), it activates the JAK-STAT signaling pathway, leading to the induction of interferon-stimulated genes (ISGs) that inhibit viral replication, suppress cell proliferation, and enhance the host immune response. Intefen is indicated for the treatment of chronic hepatitis B and C, as well as various malignancies including hairy cell leukemia, genital warts, and certain types of lymphoma. It is formulated as a solution for intramuscular, subcutaneous, or intralesional administration.
- Brand names
- Intefen
- Other names
- recombinant human interferon alpha-2aIFN-alpha-2aIFN-alpha2aIFN-alpha 2a
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on Intefen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intefen.